1. Home
  2. EDSA vs AEHL Comparison

EDSA vs AEHL Comparison

Compare EDSA & AEHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EDSA
  • AEHL
  • Stock Information
  • Founded
  • EDSA 2015
  • AEHL 1993
  • Country
  • EDSA Canada
  • AEHL China
  • Employees
  • EDSA N/A
  • AEHL N/A
  • Industry
  • EDSA Biotechnology: Pharmaceutical Preparations
  • AEHL Building Materials
  • Sector
  • EDSA Health Care
  • AEHL Industrials
  • Exchange
  • EDSA Nasdaq
  • AEHL Nasdaq
  • Market Cap
  • EDSA 17.5M
  • AEHL 17.3M
  • IPO Year
  • EDSA N/A
  • AEHL 2007
  • Fundamental
  • Price
  • EDSA $2.72
  • AEHL $3.71
  • Analyst Decision
  • EDSA Strong Buy
  • AEHL
  • Analyst Count
  • EDSA 2
  • AEHL 0
  • Target Price
  • EDSA $13.00
  • AEHL N/A
  • AVG Volume (30 Days)
  • EDSA 121.9K
  • AEHL 318.8K
  • Earning Date
  • EDSA 08-08-2025
  • AEHL 09-25-2025
  • Dividend Yield
  • EDSA N/A
  • AEHL N/A
  • EPS Growth
  • EDSA N/A
  • AEHL N/A
  • EPS
  • EDSA N/A
  • AEHL N/A
  • Revenue
  • EDSA N/A
  • AEHL $98,773,000.00
  • Revenue This Year
  • EDSA N/A
  • AEHL N/A
  • Revenue Next Year
  • EDSA N/A
  • AEHL N/A
  • P/E Ratio
  • EDSA N/A
  • AEHL N/A
  • Revenue Growth
  • EDSA N/A
  • AEHL 36.99
  • 52 Week Low
  • EDSA $1.55
  • AEHL $1.79
  • 52 Week High
  • EDSA $4.49
  • AEHL $32.80
  • Technical
  • Relative Strength Index (RSI)
  • EDSA 62.87
  • AEHL 51.57
  • Support Level
  • EDSA $2.47
  • AEHL $3.32
  • Resistance Level
  • EDSA $2.82
  • AEHL $3.60
  • Average True Range (ATR)
  • EDSA 0.18
  • AEHL 0.31
  • MACD
  • EDSA 0.03
  • AEHL 0.02
  • Stochastic Oscillator
  • EDSA 85.46
  • AEHL 65.02

About EDSA Edesa Biotech Inc.

Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.

About AEHL Antelope Enterprise Holdings Limited

Antelope Enterprise Holdings Ltd operates in two reportable operating segments: 1) business management consulting, information system technology consulting services including the sales of software use rights for digital data deposit platforms and asset management systems, and online social media platform development and consulting, and 2) natural gas power generation, which was in the initial development stage. The business of the Company is engaged in the PRC and U.S.

Share on Social Networks: